A Phase 1, Single-Dose, Open-Label Study To Evaluate The Effect Of Renal Impairment On The Pharmacokinetics Of PF-04991532.
Phase of Trial: Phase I
Latest Information Update: 21 Feb 2012
At a glance
- Drugs PF 4991532 (Primary)
- Indications Type 2 diabetes mellitus
- Focus Pharmacokinetics
- 21 Feb 2012 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 21 Feb 2012 Actual end date (Feb 2012) added as reported by ClinicalTrials.gov.
- 21 Feb 2012 Actual patients number is 27 as reported by ClinicalTrials.gov.